# Naringin Mitigates PEDV-Induced Intestinal Damage in Suckling Piglets by Modulating Inflammatory, Antiviral, and Metabolic and Transport Pathways

**Authors:** Yanyan Zhang, Muzi Li, Zongyun Li, Zhonghua Li, Lei Wang, Di Zhao, Tao Wu, Dan Yi, Yongqing Hou

PMC · DOI: 10.3390/biom16010048 · Biomolecules · 2025-12-28

## TL;DR

Naringin helps reduce intestinal damage in piglets caused by a virus by reducing inflammation and improving gut health.

## Contribution

Naringin is shown to mitigate PEDV-induced intestinal damage by modulating inflammation, antiviral, and metabolic pathways in piglets.

## Key findings

- Naringin reduced PEDV-induced intestinal damage by improving villus height and crypt depth.
- Naringin suppressed inflammatory gene expression and enhanced antiviral responses in infected piglets.
- Naringin improved intestinal metabolism and transport functions impaired by PEDV.

## Abstract

This study evaluated the protective effects of naringin (NG) against intestinal injury in 7-day-old piglets infected with porcine epidemic diarrhea virus (PEDV). Eighteen piglets (Duroc × Landrace × Large, body weight = 2.58 ± 0.05 kg) were divided into three treatment groups based on similar body weights and equal numbers of males and females: the blank control group (CON group), the PEDV infection group (PEDV group), and the NG intervention + PEDV infection group (NG + PEDV group) (n = 6 per group). The experiment lasted for 11 days, comprising a pre-feeding period from days 0 to 3 and a formal experimental period from days 4 to 10. On days 4–10 of the experiment, piglets in the NG + PEDV group were orally administered NG (10 mg/kg). On Day 8 of the experiment, piglets in the PEDV and NG + PEDV groups were inoculated with PEDV (3 mL, 106 50% tissue culture infective dose (TCID50) per milliliter). On day 11 of the experiment, piglets were euthanized for sample collection. PEDV infection caused significant intestinal damage, including a decreased (p < 0.05) villus height in the duodenum and ileum and an increased (p < 0.05) crypt depth in all intestinal segments. This intestinal damage was accompanied by an impaired absorptive function, as indicated by reduced (p < 0.05) serum D-xylose. Further results showed that PEDV compromised the intestinal antioxidant capacity by decreasing (p < 0.05) glutathione peroxidase and catalase activities, and it stimulated the intestinal inflammatory response by upregulating (p < 0.05) the expression of key inflammatory genes, including regenerating family member 3 gamma (REG3G; duodenum, jejunum, colon), S100 calcium binding protein A9 (S100A9; ileum, colon), interleukin 1 beta (IL-1β; ileum, colon), and S100 calcium binding protein A8 (S100A8; colon). PEDV also suppressed the intestinal lipid metabolism pathway by downregulating (p < 0.05) the ileal expression of Solute Carrier Family 27 Member 4 (SLC27A4), Microsomal Triglyceride Transfer Protein (MTTP), Apolipoprotein A4 (APOA4), Apolipoprotein C3 (APOC3), Diacylglycerol O-Acyltransferase 1 (DGAT1), and Cytochrome P450 Family 2 Subfamily J Member 34 (CYP2J34). Moreover, PEDV suppressed the intestinal antiviral ability by downregulating (p < 0.05) interferon (IFN) signaling pathway genes, including MX dynamin like GTPase 1 (MX1) and ISG15 ubiquitin like modifier (ISG15) in the duodenum; weakened intestinal water and ion transport by downregulating (p < 0.05) aquaporin 10 (AQP10) and potassium inwardly rectifying channel subfamily J member 13 (KCNJ13) in the duodenum, aquaporin 7 (AQP7) and transient receptor potential cation channel subfamily V member 6 (TRPV6) in the ileum, and TRPV6 and transient receptor potential cation channel subfamily M member 6 (TRPM6) in the colon; and inhibited intestinal digestive and absorptive function by downregulating (p < 0.05) phosphoenolpyruvate carboxykinase 1 (PCK1) in the duodenum and sucrase-isomaltase (SI) in the ileum. Notably, NG effectively counteracted these detrimental effects. Moreover, NG activated the IFN signaling pathway in the jejunum and suppressed PEDV replication in the colon. In conclusion, NG alleviates PEDV-induced intestinal injury by enhancing the antioxidant capacity, suppressing inflammation, normalizing the expression of metabolic and transport genes, and improving the antiviral ability.

## Linked entities

- **Genes:** REG3G (regenerating family member 3 gamma) [NCBI Gene 130120], S100A9 (S100 calcium binding protein A9) [NCBI Gene 6280], IL1B (interleukin 1 beta) [NCBI Gene 3553], S100A8 (S100 calcium binding protein A8) [NCBI Gene 6279], SLC27A4 (solute carrier family 27 member 4) [NCBI Gene 10999], MTTP (microsomal triglyceride transfer protein) [NCBI Gene 4547], APOA4 (apolipoprotein A4) [NCBI Gene 337], APOC3 (apolipoprotein C3) [NCBI Gene 345], DGAT1 (diacylglycerol O-acyltransferase 1) [NCBI Gene 8694], CYP2J34 (cytochrome P450 family 2 subfamily J member 34) [NCBI Gene 100524750], MX1 (MX dynamin like GTPase 1) [NCBI Gene 4599], ISG15 (ISG15 ubiquitin like modifier) [NCBI Gene 9636], AQP10 (aquaporin 10) [NCBI Gene 89872], KCNJ13 (potassium inwardly rectifying channel subfamily J member 13) [NCBI Gene 3769], AQP7 (aquaporin 7) [NCBI Gene 364], TRPV6 (transient receptor potential cation channel subfamily V member 6) [NCBI Gene 55503], TRPM6 (transient receptor potential cation channel subfamily M member 6) [NCBI Gene 140803], PCK1 (phosphoenolpyruvate carboxykinase 1) [NCBI Gene 5105], SI (sucrase-isomaltase) [NCBI Gene 6476]
- **Chemicals:** naringin (PubChem CID 442428)

## Full-text entities

- **Genes:** AQP7 (aquaporin 7) [NCBI Gene 364] {aka AQP7L, AQPap, GLYCQTL}, ISG15 (ISG15 ubiquitin like modifier) [NCBI Gene 9636] {aka G1P2, IFI15, IMD38, IP17, UCRP, hUCRP}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, APOA4 (apolipoprotein A4) [NCBI Gene 337] {aka ADTKD6}, AQP10 (aquaporin 10) [NCBI Gene 89872] {aka AQPA_HUMAN}, S100A8 (S100 calcium binding protein A8) [NCBI Gene 6279] {aka 60B8AG, CAGA, CFAG, CGLA, CP-10, L1Ag}, SI (sucrase-isomaltase) [NCBI Gene 6476], MX1 (MX dynamin like GTPase 1) [NCBI Gene 4599] {aka IFI-78K, IFI78, MX, MxA, lncMX1-215}, MTTP (microsomal triglyceride transfer protein) [NCBI Gene 4547] {aka ABL, MTP}, PCK1 (phosphoenolpyruvate carboxykinase 1) [NCBI Gene 5105] {aka PCKDC, PEPCK-C, PEPCK1, PEPCKC}, REG3G (regenerating family member 3 gamma) [NCBI Gene 130120] {aka LPPM429, PAP IB, PAP-1B, PAP1B, PAPIB, REG III}, KCNJ13 (potassium inwardly rectifying channel subfamily J member 13) [NCBI Gene 3769] {aka KIR1.4, KIR7.1, LCA16, SVD}, S100A9 (S100 calcium binding protein A9) [NCBI Gene 6280] {aka 60B8AG, CAGB, CFAG, CGLB, L1AG, LIAG}, APOC3 (apolipoprotein C3) [NCBI Gene 345] {aka APOCIII, Apo-C3, ApoC-3}, TRPM6 (transient receptor potential cation channel subfamily M member 6) [NCBI Gene 140803] {aka CHAK2, HMGX, HOMG, HOMG1, HSH}, SLC27A4 (solute carrier family 27 member 4) [NCBI Gene 10999] {aka ACSVL4, FATP4, IPS}, CAT (catalase) [NCBI Gene 847], DGAT1 (diacylglycerol O-acyltransferase 1) [NCBI Gene 8694] {aka ARAT, ARGP1, DGAT, DIAR7}, TRPV6 (transient receptor potential cation channel subfamily V member 6) [NCBI Gene 55503] {aka ABP/ZF, CAT1, CATL, ECAC2, HRPTTN, HSA277909}
- **Diseases:** Intestinal Damage (MESH:D007410), Inflammatory (MESH:D007249), PEDV infection (MESH:D003967)
- **Chemicals:** lipid (MESH:D008055), NG (MESH:C005274), D-xylose (MESH:D014994)
- **Species:** Porcine epidemic diarrhea virus (no rank) [taxon 28295]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12839303/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12839303/full.md

## References

57 references — full list in the complete paper: https://tomesphere.com/paper/PMC12839303/full.md

---
Source: https://tomesphere.com/paper/PMC12839303